Patent ID: 6716878
Filing Date: 2004-04-06
Classification: A61P,C07C,C07D

Abstract:
A method for the treatment of bacterial or protozoal infections in humans and non-human mammals, which comprises administering to a subject suffering such infection an antibacterially or antiprotozoally effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt, hydrate or solvate thereof: wherein:Z represents a radical of formula â€”N(OH)CH(&boxH;O) of formula â€”C(&boxH;O)NH(OH); R1 represents hydrogen, methyl or trifluoromethyl, or, except when Z is a radical of formula â€”N(OH)CH(&boxH;O), a hydroxy or amino group; R2 represents a group R10â€”(X)nâ€”(ALK)mâ€” wherein R10 represents hydrogen, or a C1-6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, mercapto, (C1-C6)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano, nitro, oxo, â€”COOH, â€”CONH2, â€”COORA, â€”NHCORA, â€”CONHRA, â€”NHRA, â€”NRARB, or â€”CONRARB wherein RA and RB are independently a (C1-C6)alkyl group and ALK represents a straight or branched divalent C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene radical, and may be interrupted by one or more non-adjacent â€”NHâ€”, â€”Oâ€” or â€”Sâ€” linkages, X represents â€”NHâ€”, â€”Oâ€” or â€”Sâ€”, and m and n are independently 0 or 1; R3 represents the side chain of a natural or non-natural alpha amino acid; and R4 represents a radical R5â€”(ALK)pâ€” wherein ALK is as defined in relation to R2, p is 0 or 1, and R5 represents hydrogen, or a C1-6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group any of which (i) may be substituted by a group selected from (C1-C6)alkyl, phenyl, benzyl, (C1-C6)alkoxy, phenoxy, hydroxy, mercapto, (C1-C6)alkylthio, amino, halo, trifluoromethyl, cyano, nitro, oxo, â€”COOH, â€”SO2H, â€”CONH2, â€”SO2NH2, â€”CORA, â€”SORA, â€”SO2RA, â€”SO2RA, â€”COORA, â€”CONHRA, â€”SO2NHRA, â€”NHCORA, â€”NHSO2RA, and â€”NHRA, wherein RA is (C1-C6)alkyl, cycloalkyl, phenyl, 2-, 3- or 4-pyridyl, N- or 2-, 3- or 4-piperidyl, N- or 2- or 3-piperazyl group; or (ii) may be substituted by â€”NRARB, â€”CONRARB or â€”SO2NRARB, wherein RA and RB are independently (C1-C6)alkyl, cycloalkyl, phenyl, 2-, 3- or 4-pyridyl, N- or 2-, 3- or 4-piperidyl, N- or 2- or 3-piperazyl group, or when taken together with the N atom to which they are attached RA and RB form a 5 to 7 membered aromatic or non-aromatic ring, which ring (a) may contain additional heteroatoms selected from N, O and S, and in which any S atom may be oxidised as a sulphonyl or sulphoxide, and (b) may be substituted on a ring carbon or heteroatom by one or more of the substituents listed under (i) above.